1.Mechanism of Jinshui Huanxian Component Formula Ⅱ Combined with Matrix Softening in Ameliorating Pulmonary Fibrosis Through Inhibition of Epithelial-mesenchymal Transition
Xiaojie WU ; Mingyan LI ; Shiyu KUANG ; Xiling PENG ; Xiaorong HOU ; Han LIU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(18):108-121
ObjectiveTo determine whether Jinshui Huanxian component formula Ⅱ (ECC-JHF Ⅱ) and matrix hardness interfere with the process of epithelial-mesenchymal transition (EMT) during pulmonary fibrosis by regulating integrin β1 (ITG β1), and to elucidate the underlying mechanism. MethodsA pulmonary fibrosis mouse model was established by a single intratracheal instillation of bleomycin (BLM). To observe the disease progression at various time points, the mice were sacrificed before modeling and on days 7, 14, 21, 28 and 42 after modeling for assessment of relevant indicators. To evaluate the therapeutic effect of drug intervention, the mice were given ECC-JHF Ⅱ and pirfenidone (PFD) by gavage starting on day 29 after modeling for 14 days of treatment, after which the mice were sacrificed. Pulmonary function, pathological changes, collagen deposition, lung tissue hardness and EMT markers were detected. Polyethylene glycol (PEG) composite hydrogels with different hardness were prepared in vitro using biomaterials such as eight-arm polyethylene glycol thiol (PEG-SH) and eight-arm polyethylene glycol maleimide (PEG-MAL). Human type Ⅱ alveolar epithelial cells cultured in hard matrix culture dishes were treated with low, medium, and high doses of ECC-JHF Ⅱ (15.31, 30.63, 61.25 mg·L-1) to observe the intervention effect of ECC-JHF Ⅱ on EMT induced by transforming growth factor beta 1 (TGF-β1). Human type Ⅱ alveolar epithelial cells cultured on soft (3.8 kPa) and hard (culture dishes, ~ GPa) matrices were treated with ECC-JHF Ⅱ, respectively. The mRNA and fluorescence expression levels of the epithelial marker E-cadherin (CDH1), the mesenchymal marker N-cadherin (CDH2) and vimentin (VIM), as well as ITG β1, were detected by real-time quantitative polymerase chain reaction (Real-time PCR) and immunofluorescence. Western blot was used to detect the protein expression of CDH1, CDH2 and ITG β1, and the biomechanical mechanism of ECC-JHF Ⅱ on EMT and pulmonary fibrosis was further verified by knocking down and specific activation of ITG β1. ResultsECC-JHF Ⅱ treatment improved BLM-induced pulmonary fibrosis in mice, as evidenced by significantly increased minute ventilation (MV) and 50% expiratory flow at tidal volume (EF50) (P<0.05), and significantly increased tidal volume (TV) after treatment (P<0.01) compared with the model group. Immunohistopathological analysis revealed attenuated inflammation and alveolar injury, reduced deposition of type Ⅰ collagen (Col-Ⅰ), and significantly decreased lung tissue stiffness (P<0.01), thereby alleviating disease progression. The real-time PCR results showed that, compared with the model group, the ECC-JHF Ⅱ group showed increased CDH1 expression and decreased CDH2 and VIM expression in mouse lung tissues (P<0.05, P<0.01), indicating that ECC-JHF Ⅱ inhibited the EMT process to ameliorate pulmonary fibrosis. In vitro experimental results showed that both ECC-JHF Ⅱ and matrix softening reversed the EMT phenotype switch. Specifically, compared with the hard matrix group, the cells cultured on the soft matrix exhibited significantly upregulated expression of the epithelial marker CDH1 (P<0.01) and significantly downregulated expression of the mesenchymal markers CDH2 and VIM (P<0.05). Furthermore, ECC-JHF Ⅱ inhibited the expression of ITG β1 both in vitro and in vivo. Knockdown and specific activation of ITG β1 further confirmed that ITG β1 is involved in the regulatory process by which ECC-JHF Ⅱ inhibits EMT and ameliorates pulmonary fibrosis
2.Rho/ROCK:key Mediator of Pulmonary Fibrosis and New Target of TCM for IPF Prevention and Treatment
Yuanyuan WU ; Kangchen LI ; Mingyan LI ; Xiling PENG ; Feifan ZHANG ; Han LIU
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(4):256-265
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by dyspnea and progressive deterioration of lung function, which significantly impacts patients' quality of life and imposes a major burden on society. Although modern medicine has increasingly enriched the treatment options for pulmonary fibrosis, unfavorable factors such as high costs and significant side effects contribute to the persistently low survival rate of patients. Studies have shown that the occurrence and development of pulmonary fibrosis are closely related to abnormalities in multiple pathways. Among these, Rho/Rho-associated coiled-coil protein kinase (ROCK) plays a key role in the disease progression of IPF by regulating the cytoskeleton. This pathway not only transmits biochemical molecular signals that promote the progress of fibrosis but also responds to the biomechanical environment, such as the increased lung tissue stiffness caused by the deposition of extracellular matrix (ECM) during the process of pulmonary fibrosis. Therefore, research on this pathway is of great significance for the prevention and treatment of IPF. In recent years, traditional Chinese medicine (TCM) has shown remarkable effects in preventing and treating IPF. Many TCM compounds and active components can reduce the production of α-smooth muscle actin (α-SMA), CollagenⅠ (ColⅠ), ColⅢ, and inflammatory factors in lung tissue by regulating the Rho/ROCK signaling pathway. These compounds inhibit the transformation of fibroblasts (FBs) into myofibroblasts (MyoFBs), intervening in the process of pulmonary fibrosis. Based on this, the article briefly reviews relevant research from recent years, discusses the key role of the Rho/ROCK pathway in pulmonary fibrosis from an interdisciplinary perspective, and summarizes the mechanisms through which TCM regulates Rho/ROCK to prevent and treat IPF, based on resources from PubMed, CNKI, and other databases, in order to provide important references for the broader clinical application of TCM in the prevention and treatment of IPF.
3.LIU Fengbin's Experience in Treating Autoimmune Liver Disease with the Method of Nourishing Yin and Removing Stasis Based on Stage
Xiling YANG ; Qiuhong YONG ; Chaoyuan HUANG ; Lina ZHAO ; Yiyuan ZHENG ; Chong PENG ; Kunhai ZHUANG ;
Journal of Traditional Chinese Medicine 2025;66(7):674-679
This paper summarizes Professor LIU Fengbin's clinical experience in treating autoimmune liver disease (AILD) using the method of nourishing yin and removing stasis based on stage differentiation. He believes that the pathogenesis of AILD generally involves both deficiency in essence and excess in manifestation, with essence deficiency often presenting as liver and kidney yin deficiency, which may progress to spleen deficiency and yang deficiency over time. The excess manifestation commonly includes qi stagnation, blood stasis, damp-heat, and phlegm toxicity. Clinically, he advocates for the treatment principle of nourishing yin and removing stasis. On the foundation of nourishing liver and kidney yin, different pathological factors causing stasis are eliminated according to their nature. Treatment is also tailored to different stages of AILD. In the early and asymptomatic stages, liver qi stagnation and spleen deficiency are prominent, warranting a therapeutic approach of soothing the liver, regulating qi and strengthening the spleen. The modified Chaishao Qizhi Decoction (柴芍气滞汤) is used. During the symptomatic stage, pathogenic factors become more pronounced, often accompanied by a significant deficiency of vital qi, with damp-heat, water retention, and phlegm toxicity as key pathological features. The treatment should focus on strengthening the spleen and dispelling dampness, using modified Sijunzi Decoction (四君子汤) combined with Yinchen Wuling Powder (茵陈五苓散). In the liver function decompensation stage, vital qi is severely deficient while pathogenic factors persist, with damp-heat, phlegm toxicity, and blood stasis obstructing the liver collaterals. Treatment should focus on nourishing blood, softening the liver, strengthening the spleen, and resolving stasis, using the modified Ruangan Yangxue Decoction (软肝养血汤). Throughout the treatment process, emphasis is placed on tonifying the liver and kidneys while protecting yin fluids.
4.Analysis of urban cancer screening results in Qinghai Province from 2019 to 2024
Peng WENGANG ; Jin SHENGYAN ; Qiao WENJIE ; Cai BAOJIA ; Yu PENGJIE ; Zhu SHENGMAO ; Han JINGJUN ; Li XILING ; Chang HAODONG ; Sun DEXIAN ; Song YINGHENG ; Rong QINGXI ; Zhang CHENGWU ; Ma XIAOMING
Chinese Journal of Clinical Oncology 2025;52(18):944-949
Objective:To analyze the screening results of the Urban Cancer Early Diagnosis and Treatment Project in Qinghai Province from 2019 to 2024.Methods:A summary and statistical analysis were conducted on six years of screening data from the Urban Cancer Early Dia-gnosis and Treatment Program in Qinghai Province,with the high-risk rate,screening rate,and detection rate calculated separately for each type of cancer.Results:From 2019 to 2024,56,882 high-risk individuals were identified.The high-risk rates for lung,colorectal,breast,up-per gastrointestinal,and liver cancer were 22.02%,21.57%,14.23%,13.52%,and 6.10%,respectively.Overall,13,592 individuals com-pleted clinical screening,with detection rates of 0.32%for lung cancer,0.41%for liver cancer,0.08%for precancerous gastric lesions,3.63%for precancerous colorectal lesions,0.08%for esophageal cancer,0.16%for gastric cancer,and 0.14%for colorectal cancer.Conclusions:The implementation of the Urban Cancer Early Diagnosis and Treatment Program in Qinghai Province aids in the early detection of cancer,improves early diagnosis and survival rates,and reduces mortality.Nevertheless,due to low public awareness and limited participation,en-hancements in program management and public outreach are required.
5.Diagnostic performance evaluation of artificial intelligence-assisted diagnostic systems in cervical cytopathological examination
Zichen YE ; Yihui YANG ; Lian XU ; Ronggan WEI ; Xiling RUAN ; Peng XUE ; Yu JIANG ; Youlin QIAO
Chinese Journal of Epidemiology 2025;46(3):499-505
Objective:To evaluate the diagnostic performance of artificial intelligence-assisted diagnostic systems in cervical cytopathological examination.Methods:Cervical cytology slide data were retrospectively collected from four hospitals for the external validation of the developed artificial intelligence-assisted diagnostic system. Subsequently, prospective data collection was conducted for human-machine assisted studies.Results:In the retrospective study, a total of 3 162 valid samples were collected as external validation data. The system showed an area under the curve (AUC) of 0.890 (95% CI: 0.878-0.902), accuracy of 0.885 (95% CI: 0.873-0.896), sensitivity of 0.928 (95% CI: 0.914-0.941), and specificity of 0.852 (95% CI: 0.834-0.867). In the prospective study, 212 valid samples were collected, and five junior cytologists participated in the human-machine assisted study. Without artificial intelligence assistance, the average AUC for the five cytologists was 0.686 (95% CI: 0.650-0.722), the accuracy was 0.699 (95% CI: 0.671-0.727), the sensitivity was 0.653 (95% CI: 0.599-0.703), the specificity was 0.719 (95% CI: 0.685-0.750), the Fleiss κ value was 0.510, and the reading time was 223 seconds. With artificial intelligence assistance, the AUC, accuracy, sensitivity, and specificity increased by 0.166, 0.143, 0.225, and 0.107, respectively. Additionally, Fleiss κ was 0.730 and the reading time decreased by 188 seconds. All differences were statistically significant (all P<0.001). Conclusions:Artificial intelligence-assisted diagnosis system shows excellent performance and good generalizability, significantly improving the diagnostic accuracy, consistency, and efficiency of junior cytologists. It can be an effective auxiliary tool for junior cytologists in clinical practice.
6.Diagnostic performance evaluation of artificial intelligence-assisted diagnostic systems in cervical cytopathological examination
Zichen YE ; Yihui YANG ; Lian XU ; Ronggan WEI ; Xiling RUAN ; Peng XUE ; Yu JIANG ; Youlin QIAO
Chinese Journal of Epidemiology 2025;46(3):499-505
Objective:To evaluate the diagnostic performance of artificial intelligence-assisted diagnostic systems in cervical cytopathological examination.Methods:Cervical cytology slide data were retrospectively collected from four hospitals for the external validation of the developed artificial intelligence-assisted diagnostic system. Subsequently, prospective data collection was conducted for human-machine assisted studies.Results:In the retrospective study, a total of 3 162 valid samples were collected as external validation data. The system showed an area under the curve (AUC) of 0.890 (95% CI: 0.878-0.902), accuracy of 0.885 (95% CI: 0.873-0.896), sensitivity of 0.928 (95% CI: 0.914-0.941), and specificity of 0.852 (95% CI: 0.834-0.867). In the prospective study, 212 valid samples were collected, and five junior cytologists participated in the human-machine assisted study. Without artificial intelligence assistance, the average AUC for the five cytologists was 0.686 (95% CI: 0.650-0.722), the accuracy was 0.699 (95% CI: 0.671-0.727), the sensitivity was 0.653 (95% CI: 0.599-0.703), the specificity was 0.719 (95% CI: 0.685-0.750), the Fleiss κ value was 0.510, and the reading time was 223 seconds. With artificial intelligence assistance, the AUC, accuracy, sensitivity, and specificity increased by 0.166, 0.143, 0.225, and 0.107, respectively. Additionally, Fleiss κ was 0.730 and the reading time decreased by 188 seconds. All differences were statistically significant (all P<0.001). Conclusions:Artificial intelligence-assisted diagnosis system shows excellent performance and good generalizability, significantly improving the diagnostic accuracy, consistency, and efficiency of junior cytologists. It can be an effective auxiliary tool for junior cytologists in clinical practice.
7.Analysis of urban cancer screening results in Qinghai Province from 2019 to 2024
Peng WENGANG ; Jin SHENGYAN ; Qiao WENJIE ; Cai BAOJIA ; Yu PENGJIE ; Zhu SHENGMAO ; Han JINGJUN ; Li XILING ; Chang HAODONG ; Sun DEXIAN ; Song YINGHENG ; Rong QINGXI ; Zhang CHENGWU ; Ma XIAOMING
Chinese Journal of Clinical Oncology 2025;52(18):944-949
Objective:To analyze the screening results of the Urban Cancer Early Diagnosis and Treatment Project in Qinghai Province from 2019 to 2024.Methods:A summary and statistical analysis were conducted on six years of screening data from the Urban Cancer Early Dia-gnosis and Treatment Program in Qinghai Province,with the high-risk rate,screening rate,and detection rate calculated separately for each type of cancer.Results:From 2019 to 2024,56,882 high-risk individuals were identified.The high-risk rates for lung,colorectal,breast,up-per gastrointestinal,and liver cancer were 22.02%,21.57%,14.23%,13.52%,and 6.10%,respectively.Overall,13,592 individuals com-pleted clinical screening,with detection rates of 0.32%for lung cancer,0.41%for liver cancer,0.08%for precancerous gastric lesions,3.63%for precancerous colorectal lesions,0.08%for esophageal cancer,0.16%for gastric cancer,and 0.14%for colorectal cancer.Conclusions:The implementation of the Urban Cancer Early Diagnosis and Treatment Program in Qinghai Province aids in the early detection of cancer,improves early diagnosis and survival rates,and reduces mortality.Nevertheless,due to low public awareness and limited participation,en-hancements in program management and public outreach are required.
8.Bioactive neolignans and lignans from the roots of Paeonia lactiflora.
Huan XIA ; Jing-Fang ZHANG ; Ling-Yan WANG ; Gui-Yang XIA ; Ya-Nan WANG ; Yu-Zhuo WU ; Peng-Cheng LIN ; Liang XIONG ; Sheng LIN
Chinese Journal of Natural Medicines (English Ed.) 2022;20(3):210-214
Two new neolignans and one new lignan (1-3) were obtained from the roots of Paeonia lactiflora. Their structures were unambiguously elucidated based on extensive spectroscopic analysis, single-crystal X-ray crystallography, and the calculated and experimental electronic circular dichroism (ECD) spectra. Compound 1 was a racemic mixture and successfully resolved into the anticipated enantiomers via chiral-phase HPLC. Compound 3 demonstrated moderate inhibitory activity against human carboxylesterase 2A1 (hCES2A1) with an IC50 value of 7.28 ± 0.94 μmol·-1.
Chromatography, High Pressure Liquid
;
Humans
;
Lignans/chemistry*
;
Paeonia
;
Plant Roots/chemistry*
;
Stereoisomerism
9.Correlation between quality of life and joint health status of adult hemophilia patients
Yanxue WANG ; Xiaojing XU ; Zhaohui YANG ; Gang WANG ; Xiling XIAO ; Xiaoxuan XIA ; Xuan PENG
Chinese Journal of Postgraduates of Medicine 2018;41(3):256-259
Objective To investigate the correlation between the quality of life and joint health status of adult hemophilia patients. Methods Forty-nine adult hemophilia patients were selected.The quality of life and joint health status of patients were evaluated by hemophilia-specific health related quality of life questionnaire for adults (Hemo-QOL-A) and hemophilia joint health score (HJHS). Results The Hemo-QOL-A score of adult hemophilia patients was (39.34 ± 18.97) scores, and HJHS score was(33.16 ± 13.17)scores.The Pearson correlation analysis result showed that Hemo-QOL-A score was positively related with HJHS score (r = 0.490, P<0.05), and Hemo-QOL-A score was positively correlated with muscular condition,joint activity and joint friction sound score of HJHS score(r=0.469, 0.396 and 0.290; P<0.05). Hemo-QOL-A score was not correlated with swelling, swelling duration, arthralgia and gait of HJHS score (P>0.05). In 294 joints of 49 patients, the total abnormal rate of the joint was 82.7%(243/294),the abnormal rate of the elbow joint was 72.4%(71/98),the abnormal rate of the knee joint was 90.8%(89/98),and the abnormal rate of ankle joint was 84.7%(83/98).Conclusions Decreased joint health status, mainly including the surrounding muscle condition and joint mobility, results in lower quality of life in patients with hemophilia.

Result Analysis
Print
Save
E-mail